Paper Details

  1. Home
  2. Paper Details

Effects of hepatic impairment on the pharmacokinetics of nilotinib: an open-label, single-dose, parallel-group study.

Author: FisherDeirdre, GallagherNeil, HeumanDouglas, LinTsu-Han, SchranHorst, SethuramanVenkat, TanakaChiaki, YinOphelia Q P, ZhouWei

Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

Nilotinib is a second-generation BCR-ABL tyrosine kinase inhibitor for treating imatinib-resistant chronic myeloid leukemia. It's primarily metabolized in the liver by cytochrome P450 3A4. Interpatient variability in systemic nilotinib exposure ranges from 32% to 64%.
Paper Details　
Original Abstract of the Article :
Nilotinib is a second-generation BCR-ABL tyrosine kinase inhibitor approved for the treatment of patients who have imatinib-resistant Philadelphia chromosome-positive chronic myeloid leukemia in the chronic or accelerated phase or who are unable to tolerate imatinib. Nilotinib is metabolized in the ...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1016/j.clinthera.2009.11.015

データ提供：米国国立医学図書館（NLM）

Nilotinib Pharmacokinetics: A Journey Through the Desert of Liver Metabolism

The liver, like a busy oasis in the desert of metabolism, plays a crucial role in processing medications. This study investigates the effects of hepatic impairment on the pharmacokinetics of nilotinib, a tyrosine kinase inhibitor used to treat chronic myeloid leukemia. The authors conducted an open-label, single-dose, parallel-group study to assess the impact of liver function on nilotinib metabolism. Their findings highlight the importance of considering individual patient characteristics when determining appropriate dosages and monitoring drug efficacy.

Navigating the Desert of Metabolism: Understanding Individual Differences

Nilotinib is primarily metabolized by the CYP3A4 enzyme in the liver. The study found that patients with hepatic impairment may experience altered nilotinib pharmacokinetics, potentially affecting drug efficacy and safety. The researchers emphasize the importance of personalized medication management to ensure optimal treatment outcomes.

Staying Hydrated in the Desert of Medications: The Importance of Monitoring

Monitoring drug levels and adjusting dosages as needed can help ensure optimal treatment outcomes and minimize potential complications. Regular monitoring, especially for patients with hepatic impairment, is essential for ensuring medication safety and efficacy.

Dr. Camel's Conclusion

The desert of metabolism is a complex and dynamic landscape, with each individual's journey through it unique. This study underscores the importance of understanding how liver function can influence drug metabolism and the need for personalized medication management to optimize treatment outcomes and ensure safety.

Date :
  1. Date Completed 2010-02-18
  2. Date Revised 2022-01-14
Further Info :

Pubmed ID

20110053

DOI: Digital Object Identifier

10.1016/j.clinthera.2009.11.015

Related Literature

Article Analysis
・Effects of nilotinib
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.